Sy, Michael
Newton, Barbara L.
Pawling, Judy
Hayama, Ken L.
Cordon, Andres
Yu, Zhaoxia
Kuhle, Jens
Dennis, James W.
Brandt, Alexander U.
Demetriou, Michael
Funding for this research was provided by:
National Center for Complementary and Integrative Health (R01AT007452)
Article History
Received: 1 August 2023
Accepted: 7 September 2023
First Online: 13 September 2023
Declarations
:
: The trial was performed under Investigational New Drug (IND) #122235 and the University of California, Irvine (UCI) Investigational Review Board (IRB) #2015–2077. All study participants gave written informed consent, and the study was conducted in conformity with the 1964 Declaration of Helsinki. The trial was peer reviewed by National Institutes of Health and funded by the National Center for Complementary and Integrative Health, with the trial made public prior to first patient enrollment via NIH-RePORTER.
: MS, AUB, JWD and MD are named as inventors on a patent application that describes GlcNAc as a biomarker for progressive multiple sclerosis. JD and MD are named as inventors on a patent for use of GlcNAc in multiple sclerosis.